Trametinib (GSK1120212) in the treatment of melanoma

Bibliography

• Middleton MR, Grob JJ, Aaronson N, Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66
   PubMed Web of Science ®Google Scholar
• Mouawad R, Sebert M, Michels J, Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol 2010;74:27-39
   PubMed Web of Science ®Google Scholar
• Bedikian AY, Millward M, Pehamberger H, Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24:4738-45
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob JJ, Demidov LV, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012;380:358-65
   PubMed Web of Science ®Google Scholar
• Hersh E, Del Vecchio M, Brown M, Phase 3, randomized, open-label, multicenter trial of nab-paclitaxel (nab-P) vs dacarbazine (DTIC) in previously untreated patients with metastatic malignant melanoma (MMM). Pigment Cell Melanoma Res 2012;25:863
   Google Scholar
• Rosenberg SA, Yang JC, Topalian SL, Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994;271:907-13
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54
   PubMed Web of Science ®Google Scholar
• Hingorani SR, Jacobetz MA, Robertson GP, Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 2003;63:5198-202
   PubMed Web of Science ®Google Scholar
• Ikenoue T, Hikiba Y, Kanai F, Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation. Cancer Res 2004;64:3428-35
   PubMed Web of Science ®Google Scholar
• Wan PT, Garnett MJ, Roe SM, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 2012;30(Suppl):abstract 8502
   Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773:1263-84
   PubMed Web of Science ®Google Scholar
• Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279-90
   PubMed Web of Science ®Google Scholar
• Pratilas CA, Solit DB. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 2010;16:3329-34
   PubMed Web of Science ®Google Scholar
• Solit DB, Garraway LA, Pratilas CA, BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-62
   PubMed Web of Science ®Google Scholar
• Crews CM, Alessandrini A, Erikson RL. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 1992;258:478-80
   PubMed Web of Science ®Google Scholar
• Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors 2006;24:21-44
   PubMed Web of Science ®Google Scholar
• Curtin JA, Fridlyand J, Kageshita T, Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk CD, Bezrookove V, Green G, Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457:599-602
   PubMed Web of Science ®Google Scholar
• Rimoldi D, Salvi S, Lienard D, Lack of BRAF mutations in uveal melanoma. Cancer Res 2003;63:5712-15
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk CD, Griewank KG, Crosby MB, Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363:2191-9
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Bastholt L, Robert C, Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012;18:555-67
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Krishnamurthi SS, Rinehart JJ, Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010;16:1924-37
   PubMed Web of Science ®Google Scholar
• Lorusso PM, Adjei AA, Varterasian M, Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005;23:5281-93
   PubMed Web of Science ®Google Scholar
• Haura EB, Ricart AD, Larson TG, A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16:2450-7
   PubMed Web of Science ®Google Scholar
• Gilmartin AG, Bleam MR, Groy A, GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011;17:989-1000
   PubMed Web of Science ®Google Scholar
• Pratilas CA, Taylor BS, Ye Q, (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 2009;106:4519-24
   PubMed Web of Science ®Google Scholar
• Alessi DR, Cuenda A, Cohen P, PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489-94
   PubMed Web of Science ®Google Scholar
• Favata MF, Horiuchi KY, Manos EJ, Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-32
   PubMed Web of Science ®Google Scholar
• Infante JR, Fecher LA, Falchook GS, Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012;13:773-81
   PubMed Web of Science ®Google Scholar
• Falchook GS, Lewis KD, Infante JR, Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012;13(8):782-9
   PubMed Web of Science ®Google Scholar
• Kim KB, Lewis K, Pavlick AC, A Phase II study of the MEK1/MEK2 inhibitor GSK1120212 in metastatic BRAF V600E or K mutant cutaneous melanoma patients previously treated with or without a BRAF inhibitor [abstract. LBA 1021-1023]. Pigment Cell Melanoma Res 2011;24(5):1021
   Google Scholar
• Flaherty KT, Puzanov I, Kim KB, Inhibition of mutated, activated braf in metastatic melanoma. N Engl J Med 2010;363:809-19
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14
   PubMed Web of Science ®Google Scholar
• McArthur GA, Ribas A, Chapman PB, Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation–positive metastatic melanoma patients (pts). J Clin Oncol 2011;29(Suppl):abstract 8502
   Google Scholar
• Nathanson KL, Martin A, Letrero R, Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol 2011;29(Suppl):abstract 8501
   Google Scholar
• Sosman JA, Pavlick AC, Schuchter LM, Analysis of molecular mechanisms of response and resistance to vemurafenib (vem) in BRAFV600E melanoma. J Clin Oncol 2012;30(Suppl):abstract 8503
   Google Scholar
• Nazarian R, Shi H, Wang Q, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010;468:973-7
   PubMed Web of Science ®Google Scholar
• Emery CM, Vijayendran KG, Zipser MC, MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009;106:20411-16
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Persaud Y, Janakiraman M, RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011;480:387-90
   PubMed Web of Science ®Google Scholar
• Johannessen CM, Boehm JS, Kim SY, COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010;468:968-72
   PubMed Web of Science ®Google Scholar
• Montagut C, Sharma SV, Shioda T, Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008;68:4853-61
   PubMed Web of Science ®Google Scholar
• Infante JR, Falchook GS, Lawrence DP, Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol 2011;29(Suppl):abstract CRA8503
   Google Scholar
• Flaherty KT, Infante JR, Daud A, Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703
   PubMed Web of Science ®Google Scholar
• Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol 2009;148:119-27
   PubMed Web of Science ®Google Scholar
• Kefford R, Arkenau H, Brown MP, Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010;28(15s Suppl):abstract 8503
   Google Scholar
• Poulikakos PI, Zhang C, Bollag G, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464:427-30
   PubMed Web of Science ®Google Scholar
• Rinehart J, Adjei AA, Lorusso PM, Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004;22:4456-62
   PubMed Web of Science ®Google Scholar
• Dahlman KB, Xia J, Hutchinson K, BRAFL597 mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2012;2:791-7
   PubMed Web of Science ®Google Scholar
• Flaherty K, Infante JR, Falchook GS, Phase I/II expansion cohort of BRAF inhibitor GSK2118436 + MEK inhibitor GSK1120212 in patients with BRAF mutant metastatic melanoma who progressed on a prior BRAF inhibitor. Pigment Cell Melanoma Res 2011;24:1022
   Google Scholar
• Ascierto PA, Berking C, Agarwala SS, Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J Clin Oncol 2012;30(Suppl):abstract 8511
   Google Scholar